Novo Nordisk has launched an audacious bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's earlier takeover agreement. This aggressive strategy marks a shift under new leadership as Novo seeks to reclaim dominance in the lucrative weight-loss drug market,

The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company's controlling shareholder, as the drugmaker looks to revive sales of its blockbuster weight-loss drug Wegovy.

Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as some U.S. states struggle with the treatment's costs.

Novo Nordisk today announced plans to present 11 abstracts at the 76th Annual American Association for the Study of Liver Diseases (AASLD) congress, The Liver Meeting® 2025, from 7 to 11 November in Washington D.

Reuters further highlighted that Novo Nordisk A/S (NYSE:NVO), which initially celebrated the success of its obesity drug, has lost the market lead to the US rival Eli Lilly and cheaper copycats, amidst pressure on prices from the US President and growing direct-to-consumer sales.

Novo Nordisk is a major drugmaker offering treatments for diabetes and weight loss. Those are two conditions affecting millions of Americans. It has some promising new treatments in development, as well.